KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Zimmer Biomet Holdings (ZBH) Research & Development (2016 - 2026)

Zimmer Biomet Holdings has reported Research & Development over the past 18 years, most recently at $103.4 million for Q1 2026.

  • For Q1 2026, Research & Development fell 6.51% year-over-year to $103.4 million; the TTM value through Mar 2026 reached $451.3 million, up 2.54%, while the annual FY2025 figure was $458.5 million, 4.82% up from the prior year.
  • Research & Development for Q1 2026 was $103.4 million at Zimmer Biomet Holdings, down from $118.7 million in the prior quarter.
  • Over five years, Research & Development peaked at $118.7 million in Q4 2025 and troughed at $96.9 million in Q1 2022.
  • A 5-year average of $109.6 million and a median of $110.4 million in 2023 define the central range for Research & Development.
  • On a YoY basis, Research & Development climbed as much as 19.63% in 2022 and fell as far as 39.76% in 2022.
  • Year by year, Research & Development stood at $108.0 million in 2022, then rose by 4.91% to $113.3 million in 2023, then decreased by 4.24% to $108.5 million in 2024, then grew by 9.4% to $118.7 million in 2025, then decreased by 12.89% to $103.4 million in 2026.
  • Business Quant data shows Research & Development for ZBH at $103.4 million in Q1 2026, $118.7 million in Q4 2025, and $115.9 million in Q3 2025.